1
|
Kato I, Ukai Y, Kondo N, Nozu K, Kimura C, Hashimoto K, Mizusawa E, Maki H, Naito A, Kawai M. Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections. J Med Chem 2021; 64:10482-10496. [PMID: 34189911 DOI: 10.1021/acs.jmedchem.1c00883] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Invasive fungal infections (IFIs) are fatal infections, but treatment options are limited. The clinical efficacies of existing drugs are unsatisfactory because of side effects, drug-drug interaction, unfavorable pharmacokinetic profiles, and emerging drug-resistant fungi. Therefore, the development of antifungal drugs with a new mechanism is an urgent issue. Herein, we report novel aryl guanidine antifungal agents, which inhibit a novel target enzyme in the ergosterol biosynthesis pathway. Structure-activity relationship development and property optimization by reducing lipophilicity led to the discovery of 6h, which showed potent antifungal activity against Aspergillus fumigatus in the presence of serum, improved metabolic stability, and PK properties. In the murine systemic A. fumigatus infection model, 6h exhibited antifungal efficacy equivalent to voriconazole (1e). Furthermore, owing to the inhibition of a novel target in the ergosterol biosynthesis pathway, 6h showed antifungal activity against azole-resistant A. fumigatus.
Collapse
Affiliation(s)
- Issei Kato
- Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Yuuta Ukai
- Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Noriyasu Kondo
- Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Kohei Nozu
- Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Chiaki Kimura
- Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Kumi Hashimoto
- Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Eri Mizusawa
- Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Hideki Maki
- Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Akira Naito
- Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Makoto Kawai
- Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| |
Collapse
|
2
|
Kronenberg E, Weber F, Schepmann D, Wünsch B. Synthesis and σ receptor affinity of spiro[[2]benzopyran-1,1'-cyclohexanes] with an exocyclic amino moiety in the 3'-position. RSC Med Chem 2020; 12:237-244. [PMID: 34046612 DOI: 10.1039/d0md00307g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Accepted: 11/15/2020] [Indexed: 11/21/2022] Open
Abstract
The main functions of σ 1 receptors include the modulation of release and reuptake of neurotransmitters, the regulation of ion channels and the influence on intracellular signaling through modulation of calcium levels. Due to these properties, σ 1 receptors are interesting drug targets for the treatment of various neurological disorders, pain and cancer. In order to modify the distance between the pharmacophoric elements (the benzene ring of 2-benzopyran and an amino moiety), a set of spiro[[2]benzopyran-1,1'-cyclohexan]-3'-amines was synthesized. The key step of the synthesis was a Parham cyclization of 1-bromo-2-(2-bromoethyl)benzene (6) with the mono ketal 7 of cyclohexane-1,3-dione, which led in a one-pot reaction to the spirocyclic framework 8. Reductive amination of ketone 9 stereoselectively provided secondary amines cis-4, which were methylated to afford tertiary amines cis-5. Whereas spirocyclic compounds cis-4a and cis-5a bearing a benzyl moiety at the exocyclic amino moiety showed rather low σ 1 affinity, the corresponding cyclohexylmethyl derivatives cis-4b and cis-5b exhibited low nanomolar σ 1 affinity. The secondary amine cis-4b displayed the highest σ 1 receptor affinity (K i = 5.4 nM) in this series. Methylation of the secondary amine cis-4b led to a slightly decreased σ 1 receptor affinity of cis-5b (K i = 15 nM).
Collapse
Affiliation(s)
- Elisabeth Kronenberg
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster Corrensstr. 48 D-48149 Münster Germany +49 251 8332144 +49 251 8333311
| | - Frauke Weber
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster Corrensstr. 48 D-48149 Münster Germany +49 251 8332144 +49 251 8333311
| | - Dirk Schepmann
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster Corrensstr. 48 D-48149 Münster Germany +49 251 8332144 +49 251 8333311
| | - Bernhard Wünsch
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster Corrensstr. 48 D-48149 Münster Germany +49 251 8332144 +49 251 8333311
| |
Collapse
|
3
|
Schepmann D, Neue C, Westphälinger S, Müller C, Bracher F, Lange C, Bednarski P, Almansa C, Friedland K, Räbiger V, Düfer M, Wünsch B. Pharmacological characterization of high-affinity σ 1 receptor ligands with spirocyclic thienopyran and thienofuran scaffold. J Pharm Pharmacol 2020; 72:236-248. [PMID: 31743446 DOI: 10.1111/jphp.13196] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2019] [Accepted: 10/21/2019] [Indexed: 12/24/2022]
Abstract
OBJECTIVES In this study, the pharmacological properties of six spirocyclic piperidines 1-6 showing very high σ1 receptor affinity (Ki = 0.2-16 nm) were investigated. METHODS In vitro receptor binding studies, retinal ganglion assay and in vivo capsaicin assay were used to determine the affinity, selectivity and activity. Influence on human tumour cell growth (cell lines A427, LCLC-103H, 5637 and DAN-G) was determined in different assays. The effect on the ergosterol and cholesterol biosynthesis was determined by GLC/MS analysis. KEY FINDINGS Receptor binding studies demonstrated high selectivity for the σ1 receptor. The increased Ca2+ influx mediated by 2 and the analgesic activity of 1, 4, 5 and 6 confirm σ1 receptor antagonistic activity. Inhibition of human tumour cell growth further supports the σ1 antagonistic effects. Treatment of A427 tumour cells with 2 led to cell detachment and cell degradation. Whereas the ergosterol biosynthesis was not affected, the sterol C14-reductase, a key enzyme in the cholesterol biosynthesis, was weakly inhibited. CONCLUSIONS Due to the high selectivity, off-target effects are not expected. The antiallodynic activity underlines the clinical potential of the spirocyclic piperidines for the treatment of neuropathic pain. Due to the antiproliferative activity, the spirocyclic σ1 antagonists represent promising antitumour agents.
Collapse
Affiliation(s)
- Dirk Schepmann
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster, Münster, Germany
| | - Christina Neue
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster, Münster, Germany
| | - Stefanie Westphälinger
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster, Münster, Germany
| | - Christoph Müller
- Department of Pharmacy - Center for Drug Research, Ludwig-Maximilians University of Munich, Munich, Germany
| | - Franz Bracher
- Department of Pharmacy - Center for Drug Research, Ludwig-Maximilians University of Munich, Munich, Germany
| | - Carsten Lange
- Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, University of Greifswald, Greifswald, Germany
| | - Patrick Bednarski
- Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, University of Greifswald, Greifswald, Germany
| | | | - Kristina Friedland
- Pharmacology and Toxicology, Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany
| | - Vivien Räbiger
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster, Münster, Germany
| | - Martina Düfer
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster, Münster, Germany
| | - Bernhard Wünsch
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster, Münster, Germany
- Cells-in-Motion Cluster of Excellence (EXC 1003 - CiM), Westfälische Wilhelms-Universität Münster, Münster, Germany
| |
Collapse
|
4
|
Franchini S, Sorbi C, Battisti UM, Tait A, Bencheva LI, Cichero E, Fossa P, Cilia A, Prezzavento O, Ronsisvalle S, Aricò G, Benassi L, Vaschieri C, Azzoni P, Magnoni C, Brasili L. Structure-Activity Relationships within a Series of σ1
and σ2
Receptor Ligands: Identification of a σ2
Receptor Agonist (BS148) with Selective Toxicity against Metastatic Melanoma. ChemMedChem 2017; 12:1893-1905. [DOI: 10.1002/cmdc.201700427] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2017] [Revised: 09/20/2017] [Indexed: 11/09/2022]
Affiliation(s)
- Silvia Franchini
- Dipartimento di Scienze della Vita; Università degli Studi di Modena e Reggio Emilia; Via Campi 103 41125 Modena Italy
| | - Claudia Sorbi
- Dipartimento di Scienze della Vita; Università degli Studi di Modena e Reggio Emilia; Via Campi 103 41125 Modena Italy
| | - Umberto Maria Battisti
- Dipartimento di Scienze della Vita; Università degli Studi di Modena e Reggio Emilia; Via Campi 103 41125 Modena Italy
| | - Annalisa Tait
- Dipartimento di Scienze della Vita; Università degli Studi di Modena e Reggio Emilia; Via Campi 103 41125 Modena Italy
| | - Leda Ivanova Bencheva
- Dipartimento di Scienze della Vita; Università degli Studi di Modena e Reggio Emilia; Via Campi 103 41125 Modena Italy
| | - Elena Cichero
- Dipartimento di Farmacia; Università degli Studi di Genova; Viale Benedetto XV 3 16132 Genova Italy
| | - Paola Fossa
- Dipartimento di Farmacia; Università degli Studi di Genova; Viale Benedetto XV 3 16132 Genova Italy
| | - Antonio Cilia
- Divisione Ricerca e Sviluppo; Recordati S.p.A.; Via Civitali 1 20148 Milano Italy
| | - Orazio Prezzavento
- Dipartimento di Scienze del Farmaco; Università degli Studi di Catania; Viale Andrea Doria 6 95125 Catania Italy
| | - Simone Ronsisvalle
- Dipartimento di Scienze del Farmaco; Università degli Studi di Catania; Viale Andrea Doria 6 95125 Catania Italy
| | - Giuseppina Aricò
- Dipartimento di Scienze del Farmaco; Università degli Studi di Catania; Viale Andrea Doria 6 95125 Catania Italy
| | - Luisa Benassi
- Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con interesse Trapiantologico, Oncologico e di Medicina Rigenerativa; Università degli Studi di Modena e Reggio Emilia; via del Pozzo 71 41124 Modena Italy
| | - Cristina Vaschieri
- Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con interesse Trapiantologico, Oncologico e di Medicina Rigenerativa; Università degli Studi di Modena e Reggio Emilia; via del Pozzo 71 41124 Modena Italy
| | - Paola Azzoni
- Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con interesse Trapiantologico, Oncologico e di Medicina Rigenerativa; Università degli Studi di Modena e Reggio Emilia; via del Pozzo 71 41124 Modena Italy
| | - Cristina Magnoni
- Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con interesse Trapiantologico, Oncologico e di Medicina Rigenerativa; Università degli Studi di Modena e Reggio Emilia; via del Pozzo 71 41124 Modena Italy
| | - Livio Brasili
- Dipartimento di Scienze della Vita; Università degli Studi di Modena e Reggio Emilia; Via Campi 103 41125 Modena Italy
| |
Collapse
|
5
|
Kokornaczyk AK, Schepmann D, Yamaguchi J, Itami K, Laurini E, Fermeglia M, Pricl S, Wünsch B. Thiazole-Based σ 1 Receptor Ligands: Diversity by Late-Stage C-H Arylation of Thiazoles, Structure-Affinity and Selectivity Relationships, and Molecular Interactions. ChemMedChem 2017; 12:1070-1080. [PMID: 28544475 DOI: 10.1002/cmdc.201700166] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2017] [Revised: 05/22/2017] [Indexed: 12/25/2022]
Abstract
Spirocyclic thiophene derivatives represent promising σ1 ligands with high σ1 affinity and selectivity over the σ2 subtype. To increase ligand efficiency, the thiophene ring was replaced bioisosterically by a thiazole ring, and the pyran ring was opened. Late-stage diversification by regioselective C-H arylation of thiazoles 9 a-c resulted in a set of 53 compounds with high diversity. This set of compounds was analyzed with respect to σ1 affinity, σ1 /σ2 selectivity, lipophilicity (logD7.4 ), lipophilicity-corrected ligand efficiency (LELP), and molecular target interactions. The most promising candidates were pyridyl-substituted thiazole derivatives 33 c (2-(1-benzyl-4-ethoxypiperidin-4-yl)-5-(pyridin-3-yl)thiazole) and 34 c (2-(1-benzyl-4-ethoxypiperidin-4-yl)-5-(pyridin-4-yl)thiazole), possessing low-nanomolar σ1 affinity (Ki =1.3 and 1.9 nm), high σ1 /σ2 selectivity (>1500-fold), low lipophilicity (logD7.4 =1.8) and very good ligand efficiency (LELP=5.5), indicating promising pharmacodynamics and pharmacokinetics. Molecular simulation studies, including docking and deconvolution of the free binding energy into its major components, led to decreased hydrophobic stabilization of pyridyl derivatives 33 c and 34 c, which was compensated by lower desolvation energy.
Collapse
Affiliation(s)
- Artur K Kokornaczyk
- Institut für Pharmazeutische und Medizinische Chemie der, Universität Münster, Corrensstraße 48, 48149, Münster, Germany
| | - Dirk Schepmann
- Institut für Pharmazeutische und Medizinische Chemie der, Universität Münster, Corrensstraße 48, 48149, Münster, Germany
| | - Junichiro Yamaguchi
- Department of Applied Chemistry, Waseda University, 3-4-1 Ohkubo, Shinjuku, Tokyo 169-8555, Japan
| | - Kenichiro Itami
- Institute of Transformative Bio-Molecules (WPI-ITbM) and Department of Chemistry, Graduate School of Science, Nagoya University, Chikusa, Nagoya, 464-8602, Japan
| | - Erik Laurini
- Molecular Simulations Engineering (MOSE) Laboratory, Department of Engineering and Architecture (DEA), University of Trieste, Via Valerio 6, 34127, Trieste, Italy
- National Interuniversity Consortium for Material Science and Technology (INSTM), Research Unit MOSE-DEA, University of Trieste, Via Valerio 6, 32127, Trieste, Italy
| | - Maurizio Fermeglia
- Molecular Simulations Engineering (MOSE) Laboratory, Department of Engineering and Architecture (DEA), University of Trieste, Via Valerio 6, 34127, Trieste, Italy
- National Interuniversity Consortium for Material Science and Technology (INSTM), Research Unit MOSE-DEA, University of Trieste, Via Valerio 6, 32127, Trieste, Italy
| | - Sabrina Pricl
- Molecular Simulations Engineering (MOSE) Laboratory, Department of Engineering and Architecture (DEA), University of Trieste, Via Valerio 6, 34127, Trieste, Italy
- National Interuniversity Consortium for Material Science and Technology (INSTM), Research Unit MOSE-DEA, University of Trieste, Via Valerio 6, 32127, Trieste, Italy
| | - Bernhard Wünsch
- Institut für Pharmazeutische und Medizinische Chemie der, Universität Münster, Corrensstraße 48, 48149, Münster, Germany
- Cells-in-Motion Cluster of Excellence (EXC 1003-CiM), Westfälische Wilhelms-Universität, Münster, Germany
| |
Collapse
|
6
|
Vela JM, Merlos M, Almansa C. Investigational sigma-1 receptor antagonists for the treatment of pain. Expert Opin Investig Drugs 2015; 24:883-96. [PMID: 26037209 DOI: 10.1517/13543784.2015.1048334] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
INTRODUCTION The sigma-1 receptor (σ1R) is a ligand-regulated molecular chaperone that interacts with other proteins, including NMDA and opioid receptors, to modulate their activity. Convergent evidence indicates that σ1R antagonists exert inhibitory effects (and agonists stimulatory effects) on pain by stepping down the intracellular signaling cascades involved in transduction of noxious stimuli and plastic changes (i.e., sensitization phenomena) associated with chronic pain states. AREAS COVERED This review addresses three primary domains. The first focuses on mechanisms underlying the antinociceptive effects of σ1R antagonists. The second addresses evidence gained using pharmacological tools and experimental drugs in the discovery phase and clinical development. Finally, the article outlines the potential benefits of σ1R antagonists, alone or in combination, in the context of available pain therapeutics. EXPERT OPINION There is a critical need for new analgesics based on new mechanisms of action. Target identification requires convincing evidence relating targets to function. In turn, target validation requires confirmation of therapeutic benefits, ideally in humans. Current preclinical evidence provides strong rationale for σ1R antagonists in pain. The outcome of clinical studies with the most advanced investigational σ1R antagonist, S1RA (E-52862), will be of great interest to ascertain the potential of this new therapeutic approach to pain management.
Collapse
Affiliation(s)
- José Miguel Vela
- ESTEVE, Drug Discovery and Preclinical Development, Carrer Baldiri Reixac , 4-8. Parc Científic de Barcelona, 08028 Barcelona , Spain +34 93 4466244 ; +34 93 4466432 ;
| | | | | |
Collapse
|
7
|
Manohar M, Banister SD, Beinat C, O'Brien-Brown J, Kassiou M. Recent Advances in the Development of Sigma-1 Receptor Ligands. Aust J Chem 2015. [DOI: 10.1071/ch14590] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The existence of two distinct sigma (σ) receptor subtypes was established in the early 1990s. Sigma-1 and sigma-2 receptors (S1Rs and S2Rs, respectively) were shown to possess distinct molecular size, anatomical distribution, and ligand discrimination. S2R is overexpressed in numerous human cancers, and has therapeutic potential for the imaging and treatment of certain tumours. In contrast, S1R is more broadly involved in a wide variety of central nervous system (CNS) diseases including motor disorders, memory deficits, depression, schizophrenia, anxiety, pain, drug addiction, and many more. Since the human S1R was cloned in 1996, numerous high affinity ligands with excellent selectivity for S1R have been developed. This review focuses on recent developments in the generation of structurally diverse S1R-selective ligands and novel therapeutic candidates targeting S1Rs.
Collapse
|
8
|
The use of spirocyclic scaffolds in drug discovery. Bioorg Med Chem Lett 2014; 24:3673-82. [DOI: 10.1016/j.bmcl.2014.06.081] [Citation(s) in RCA: 564] [Impact Index Per Article: 56.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2014] [Revised: 06/17/2014] [Accepted: 06/27/2014] [Indexed: 12/12/2022]
|
9
|
Majee D, Biswas S, Mobin SM, Samanta S. An expedient one-pot sequential three-component reaction for the stereoselective synthesis of functionalized spiro-sulfamidate imine fused δ-lactone scaffold. Tetrahedron Lett 2014. [DOI: 10.1016/j.tetlet.2014.06.088] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
10
|
Almansa C, Vela JM. Selective sigma-1 receptor antagonists for the treatment of pain. Future Med Chem 2014; 6:1179-99. [PMID: 25078137 DOI: 10.4155/fmc.14.54] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2023] Open
Abstract
The sigma-1 receptor (σ1R) is located in areas of the CNS key for pain control and belongs to a unique target class with chaperoning functions over different molecular targets involved in transmission and amplification of nociceptive messages. Preclinical evidence supports a role for σ1R antagonists in the treatment of pain states where hypersensitivity develops as hyperalgesia and allodynia, two common symptoms encountered in neuropathic and other chronic pain conditions. Additionally, σ1R antagonists increase opioid analgesia without increasing opioid-related unwanted effects, which point to their potential use as opioid adjuvant therapy. This review summarizes the structure and function of the σ1R as well as the medicinal chemistry and pharmacological studies directed to the identification of σ1R antagonists for the treatment of pain.
Collapse
Affiliation(s)
- Carmen Almansa
- Drug Discovery and Preclinical Development, ESTEVE, Baldiri Reixach, 4-8, 08028 Barcelona, Spain
| | | |
Collapse
|
11
|
Miyata K, Möller G, Schepmann D, Wünsch B. Pyridine analogues of spirocyclic σ₁ receptor ligands. Bioorg Med Chem 2014; 22:4277-84. [PMID: 24913984 DOI: 10.1016/j.bmc.2014.05.033] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2014] [Revised: 05/14/2014] [Accepted: 05/14/2014] [Indexed: 11/30/2022]
Abstract
Spirocyclic benzopyrans 2 interact with high affinity and selectivity with σ₁ receptors. Bioisosteric replacement of the benzene ring of the benzopyran substructure with the electron rich thiophene ring (3) led to increased σ₁ affinity. Herein the synthesis and pharmacological evaluation of electron deficient pyridine bioisosteres 4 are reported. Homologation of the aldehyde 6 to afford the pyridylacetaldehyde derivative 8 was performed by a Wittig reaction. Bromine lithium exchange of the bromopyridine 8, addition to 1-benzylpiperidin-4-one and cyclization led to the spirocyclic pyrranopyridine 10. Hydrogenolytic removal of the N-benzyl moiety of 10 provided the secondary amine 11, which allowed the introduction of various N-substituents (12a-d). Cyclization of the hydroxy acetal 9 with HCl led to various modifications of the substituent in 3'-position. Generally the σ₁ affinity of the pyridine derivatives is reduced compared with those of the benzene and thiophene derivatives 2 and 3. However, the relationships between the structure and the σ₁ affinity follow the same rules as for the benzene and thiophene derivatives. The most promising σ₁ ligand within this class of compounds is the pyranopyridine 15 with a double bond in the pyran ring revealing a Ki-value of 4.6 nM and a very high selectivity (>217-fold) over the σ₂ subtype.
Collapse
Affiliation(s)
- Kengo Miyata
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster, Corrensstraße 48, D-48149 Münster, Germany; Research Center for Materials Science and Department of Chemistry, Nagoya University, Chikusa-ku, Nagoya 464-8602, Japan
| | - Guido Möller
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster, Corrensstraße 48, D-48149 Münster, Germany
| | - Dirk Schepmann
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster, Corrensstraße 48, D-48149 Münster, Germany
| | - Bernhard Wünsch
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster, Corrensstraße 48, D-48149 Münster, Germany; Cells-in-Motion Cluster of Excellence (EXC 1003-CiM), University Münster, Germany.
| |
Collapse
|
12
|
Harel D, Schepmann D, Wünsch B. New combination of pharmacophoric elements of potent σ1 ligands: Design, synthesis and σ receptor affinity of aminoethyl substituted tetrahydrobenzothiophenes. Eur J Med Chem 2013; 69:490-7. [DOI: 10.1016/j.ejmech.2013.09.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2013] [Revised: 09/04/2013] [Accepted: 09/05/2013] [Indexed: 11/28/2022]
|
13
|
Ferrari FD, Pasqua AE, Ledgard AJ, Marquez R. Convergent approach to complex spirocyclic pyrans: practical synthesis of the oxa-pinnaic acid core. Org Biomol Chem 2013; 11:3469-76. [PMID: 23589153 DOI: 10.1039/c3ob40284c] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The enantioselective synthesis of the oxa-pinnaic acid framework has been achieved through internal asymmetric induction. The synthetic strategy pursued illustrates the adaptability of the Achmatowicz oxidative rearrangement for the synthesis of complex spirocyclic pyrans starting from tertiary alcohols.
Collapse
Affiliation(s)
- Frank D Ferrari
- School of Chemistry, University of Glasgow, Glasgow, G12 8QQ, UK
| | | | | | | |
Collapse
|
14
|
Hasebein P, Aulinger K, Schepmann D, Wünsch B. Heck reaction of ortho-substituted iodobenzenes with α,β-unsaturated nitriles as a key step in the synthesis of tetrahydro-2-benzazepines and hexahydro-3-benzazocines. Tetrahedron 2013. [DOI: 10.1016/j.tet.2013.04.017] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Meyer C, Neue B, Schepmann D, Yanagisawa S, Yamaguchi J, Würthwein EU, Itami K, Wünsch B. Improvement of σ1 receptor affinity by late-stage C-H-bond arylation of spirocyclic lactones. Bioorg Med Chem 2013; 21:1844-56. [PMID: 23462714 DOI: 10.1016/j.bmc.2013.01.038] [Citation(s) in RCA: 94] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2012] [Revised: 01/14/2013] [Accepted: 01/18/2013] [Indexed: 11/16/2022]
Abstract
The direct C-H-bond arylation of the complex spirocyclic lactones 13, 14, and 18 allows the introduction of diverse aryl moieties in the last step of the synthesis. A selective α-arylation of the thiophene moiety was performed with the catalytic system PdCl2/2,2'-bipyridyl/Ag2CO3, whereas the β-position of the thiophene ring was addressed by using the alternative catalytic system PdCl2/P[OCH(CF3)2]3/Ag2CO3. Due to electronic and steric reasons the arylation of the five-membered lactone 18 occurred in both α-positions providing 4'-mono-, 6'-mono- and 4',6'-diarylated thiophenes 22-26a-c. Compounds with an additional aryl moiety at the 'upper left (top)' position (1'-position of 13, 3'-position of 14, 4'-position of 18) showed increased σ1 affinity compared to the non-arylated parent compounds. A phenyl moiety at the 'left' position (2'-position in 20a) also increased the σ1 affinity but to a lower extent. A considerable reduction of σ1 affinity was observed after introducing an aryl moiety in 6'-position of 18, which might result from shielding the tertiary amine, which is crucial for interaction with the σ1 receptor. The discussion of the experimental results is supported by high-level quantum chemical DFT-calculations of the NBO-charges of 13 and 18 and the relative energies of the related arylated products.
Collapse
Affiliation(s)
- Christina Meyer
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen, Wilhelms-Universität Münster, Hittorfstraße 58-62, D-48149 Münster, Germany
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Harel D, Schepmann D, Wünsch B. Spiro[[1]benzothiophen-4,4′-piperidines] – carba analogs of potent σ1 ligands. MEDCHEMCOMM 2013. [DOI: 10.1039/c3md00228d] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
17
|
Meyer C, Schepmann D, Yanagisawa S, Yamaguchi J, Dal Col V, Laurini E, Itami K, Pricl S, Wünsch B. Pd-catalyzed direct C-H bond functionalization of spirocyclic σ1 ligands: generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the σ1 receptor. J Med Chem 2012; 55:8047-65. [PMID: 22913577 DOI: 10.1021/jm300894h] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
To explore the hydrophobic binding region of the σ(1) receptor protein, regioisomeric spirocyclic thiophenes 9-11 were developed as versatile building blocks. Regioselective α- and β-arylation using the catalyst systems PdCl(2)/bipy/Ag(2)CO(3) and PdCl(2)/P[OCH(CF(3))(2)](3)/Ag(2)CO(3) allowed the introduction of various aryl moieties at different positions in the last step of the synthesis. The increasing σ(1) affinity in the order 4 < 5/6 < 7/8 indicates that the positions of the additional aryl moiety and the S atom in the spirocyclic thiophene systems control the σ(1) affinity. The main features of the pharmacophore model developed for this class of σ(1) ligands are a positive ionizable group, a H-bond acceptor group, two hydrophobic moieties, and one hydrophobic aromatic group. Docking of the ligands into a σ(1) 3D homology model via molecular mechanics/Poisson-Boltzmann surface area calculations led to a very good correlation between the experimentally determined and estimated free energy of receptor binding. These calculations support the hypothesis of a reverse binding mode of ligands bearing the aryl moiety at the "top" (compounds 2, 3, 7, and 8) and "left" (compounds 4, 5, and 6) positions, respectively.
Collapse
Affiliation(s)
- Christina Meyer
- Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster, Hittorfstrasse 58-62, D-48149 Münster, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|